These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Alendronate for the treatment of osteoporosis in men. Olszynski WP; Davison KS Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499 [TBL] [Abstract][Full Text] [Related]
7. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969 [TBL] [Abstract][Full Text] [Related]
8. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959 [TBL] [Abstract][Full Text] [Related]
9. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248 [TBL] [Abstract][Full Text] [Related]
10. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Simon JA; Lewiecki EM; Smith ME; Petruschke RA; Wang L; Palmisano JJ Clin Ther; 2002 Nov; 24(11):1871-86. PubMed ID: 12501880 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Luckey MM; Gilchrist N; Bone HG; Davie MW; de Villiers TJ; Wu M; Daifotis AG; Santora AC; Orloff JJ Obstet Gynecol; 2003 Apr; 101(4):711-21. PubMed ID: 12681875 [TBL] [Abstract][Full Text] [Related]
12. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). Iwamoto J; Okano H; Furuya T; Urano T; Hasegawa M; Hirabayashi H; Kumakubo T; Makita K J Bone Miner Metab; 2016 Mar; 34(2):201-8. PubMed ID: 25794468 [TBL] [Abstract][Full Text] [Related]
13. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Weiss M; Vered I; Foldes AJ; Cohen YC; Shamir-Elron Y; Ish-Shalom S; Aging Clin Exp Res; 2005 Apr; 17(2):143-9. PubMed ID: 15977463 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
15. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Imai K Clin Interv Aging; 2013; 8():681-8. PubMed ID: 23766643 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. Uchida S; Taniguchi T; Shimizu T; Kakikawa T; Okuyama K; Okaniwa M; Arizono H; Nagata K; Santora AC; Shiraki M; Fukunaga M; Tomomitsu T; Ohashi Y; Nakamura T J Bone Miner Metab; 2005; 23(5):382-8. PubMed ID: 16133688 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357 [TBL] [Abstract][Full Text] [Related]
19. Alendronate: an update of its use in osteoporosis. Sharpe M; Noble S; Spencer CM Drugs; 2001; 61(7):999-1039. PubMed ID: 11434454 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. Kishimoto H; Fukunaga M; Kushida K; Shiraki M; Itabashi A; Nawata H; Nakamura T; Ohta H; Takaoka K; Ohashi Y; J Bone Miner Metab; 2006; 24(5):405-13. PubMed ID: 16937274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]